Key players include President Trump, the Department of Commerce (initiated investigation April 1, 2025; approves onshoring), Department of Health and Human Services (HHS) (MFN pricing), U.S. Customs and Border Protection (enforcement), and the White House (fact sheet).[1][2][5][7] Annexes list affected HTS codes (I), exempted products (IV), zero-tariff companies with prior agreements (II), and 100% duty firms (III); firms like those in Annex II qualify for relief via negotiations.[1][3][4]
This stems from a Commerce investigation finding U.S. reliance on foreign production—53% of patented pharmaceuticals and 85% of APIs imported—threatens national security by weakening domestic capacity for emergencies.[1][3][5] It follows "Liberation Day" tariffs (April 2, 2025) and uses Section 232 to onshore manufacturing and leverage drug pricing, with a joint Commerce-HHS report due July 1, 2026.[1][2][6]
Newsworthy now as tariffs launch in ~3.5 months (July 31), disrupting global supply chains amid Trump's trade agenda; uncertainties in approvals, enforcement, and Annex updates heighten urgency for pharma firms.[2][5][9]